BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 17, 2003
View Archived Issues
Trimeris, Roche's First-In-Class HIV Drug, Fuzeon, Approved
The FDA cleared the accelerated approval application for Fuzeon, a first-in-class fusion inhibitor for HIV-1 developed by Trimeris Inc., and partner F. Hoffmann-La Roche Ltd. (BioWorld Today)
Read More
The Medicines Co. Offering Gets $85.75M For Late-Stage Work
Read More
Activation Of Brain-Specific Genes Adds Data To Fragile X Syndrome, A Main Form Of Mental Retardation
Read More
Inspire Increases Share Amount, Raises $67.5M For Eye Products
Read More
Other News To Note
Read More